NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara by EC
January 03, 2014 at 08:34 AM EST
NPS Pharmaceuticals (NASDAQ: NPSP ) today announced that the European Commission has granted orphan drug designation to Natpara® (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.
